Randomized clinical trial: benefits of aerobic physical activity for 24 weeks in postmenopausal women with nonalcoholic fatty liver disease

Rezende, Rosamar Eulira Fontes; Duarte, Sebastião Mauro Bezerra; Stefano, José Tadeu; Roschel, Hamilton; Gualano, Bruno; Pinto, Ana Lúcia de Sá; Vezozzo, Denise Cerqueira Paranaguá; Carrilho, Flair José; Oliveira, Conceição Maria de

doi:10.1097/gme.0000000000000647

Cited by 43 publications

(53 citation statements)

References 38 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…However, only few studies have specifically assessed the role of physical activity in NAFLD prevention/reversal in postmenopausal women. Data have shown that exercise training effectively reduces liver enzymes in overweight postmenopausal women, probably as a reflection of liver fat content [224], and aerobic physical activity reduces cardiovascular risk factors in postmenopausal women with NAFLD [225]. Further studies are needed to define the ideal structure and duration of exercise-based interventions in postmenopausal women with NAFLD or at risk of developing it.…”

Section: Can Gender Dimorphism Of Nafld Be Exploited For Therapeutic mentioning

confidence: 99%

NAFLD as a Sexual Dimorphic Disease: Role of Gender and Reproductive Status in the Development and Progression of Nonalcoholic Fatty Liver Disease and Inherent Cardiovascular Risk

et al. 2017

View full text Add to dashboard Cite

Nonalcoholic fatty liver disease (NAFLD) spans steatosis through nonalcoholic steatohepatis, cirrhosis, and hepatocellular carcinoma (HCC) associated with striking systemic features and excess cardiovascular and liver-related mortality. The pathogenesis of NAFLD is complex and multifactorial. Endocrine derangements are closely linked with dysmetabolic traits. For example, in animal and human studies, female sex is protected from dysmetabolism thanks to young individuals’ ability to partition fatty acids towards ketone body production rather than very low density lipoprotein (VLDL)-triacylglycerol, and to sex-specific browning of white adipose tissue. Ovarian senescence facilitates both the development of massive hepatic steatosis and the fibrotic progression of liver disease in an experimental overfed zebrafish model. Consistently, estrogen deficiency, by potentiating hepatic inflammatory changes, hastens the progression of disease in a dietary model of nonalcoholic steatohepatitis (NASH) developing in ovariectomized mice fed a high-fat diet. In humans, NAFLD more often affects men; and premenopausal women are equally protected from developing NAFLD as they are from cardiovascular disease. It would be expected that early menarche, definitely associated with estrogen activation, would produce protection against the risk of NAFLD. Nevertheless, it has been suggested that early menarche may confer an increased risk of NAFLD in adulthood, excess adiposity being the primary culprit of this association. Fertile age may be associated with more severe hepatocyte injury and inflammation, but also with a decreased risk of liver fibrosis compared to men and postmenopausal status. Later in life, ovarian senescence is strongly associated with severe steatosis and fibrosing NASH, which may occur in postmenopausal women. Estrogen deficiency is deemed to be responsible for these findings via the development of postmenopausal metabolic syndrome. Estrogen supplementation may at least theoretically protect from NAFLD development and progression, as suggested by some studies exploring the effect of hormonal replacement therapy on postmenopausal women, but the variable impact of different sex hormones in NAFLD (i.e., the pro-inflammatory effect of progesterone) should be carefully considered.

show abstract

Section: Can Gender Dimorphism Of Nafld Be Exploited For Therapeutic mentioning

confidence: 99%

NAFLD as a Sexual Dimorphic Disease: Role of Gender and Reproductive Status in the Development and Progression of Nonalcoholic Fatty Liver Disease and Inherent Cardiovascular Risk

et al. 2017

View full text Add to dashboard Cite

show abstract

“…In general, the management of fatty liver disease primarily depends on intense lifestyle changes to lose weight, but many different drugs (including incretin-based drugs, insulin sensitizers, antioxidants, lipid lowering agents, and weight loss medications) and bariatric surgery or liver transplantation have emerged, which represent therapeutic options that may be added to TLC when necessary for the management of the disease 5,27 . Notably, numerous studies have documented correlations between the therapeutic effect of Silybin on treating NAFLD with its special properties 28 .…”

Section: Discussionmentioning

confidence: 99%

Effect of silibinin capsules combined with lifestyle modification on hepatic steatosis in patients with chronic hepatitis B

Wang

Chen

et al. 2021

Sci Rep

View full text Add to dashboard Cite

The coexistence of HBV infection and hepatic steatosis is a novel characteristic of liver disease. Silibinin capsules (SC) is a silybin-phospholipid complex containing silybin as the bioactive component, which exerts a remarkable biological effect on various liver diseases, including nonalcoholic fatty liver disease (NAFLD). The purpose of this study was to investigate (1) the prevalence of hepatic steatosis in the general population and patients with chronic hepatitis B (CHB) and (2) to evaluate the effect of SC combined with therapeutic lifestyle changes (TLC) compared with TLC alone on hepatic steatosis in patients with CHB. A total of 16,451 individuals underwent transient elastography (TE) with the control attenuation parameter (CAP) measurement, among which the prevalence of hepatic steatosis was 31.1% in patients with CHB and 42.2% in the general population. The prevalence of hepatic steatosis differed between patients with CHB and the general population at an age of 40 years or older but was similar in individuals aged 39 years or younger (p < 0.05). Furthermore, in patients with CHB presenting hepatic steatosis, the post-6-month relative reduction in CAP in the SC combined with TLC group (p = 0.001) was significantly greater than in the TLC alone group (p = 0.183). The CAP distribution of different steatosis grades (S1, S2, and S3) in the SC combined with TLC group was decreased and S0 (CAP < 248 dB/m) increased significantly, but not significant in the TLC group. Thus, SC combined with TLC may effectively improve hepatic steatosis in patients with CHB.

show abstract

“…To our knowledge, only three studies have investigated the effects of exercise on advanced stages of NAFLD, that is, fibrosis, with promising results. 103,110,111 The majority of studies of the gut microbiome of patients with NAFLD focus mainly on taxonomy level instead of the functional capacities; this is unfortunate because the functional capacities of the microbiome may hold more mechanistic information. Currently, there are not enough available studies with appropriate settings investigating the exercise-mediated effects on the gut microbiome for clear conclusions in patients with NAFLD.…”

Section: Discussionmentioning

confidence: 99%

“…Another study did not find any significant improvements in liver fibrosis assessed by VCTE when comparing baseline and endpoint upon exercise. 110 On the other hand, promising results were presented from a 12-week aerobic-exercise intervention with significantly reduced fibrosis at endpoint biopsies, as well as improved liver stiffness scores measured with VCTE, and improved steatosis measured with controlled attenuation parameter (CAP). 111 With respect to the effect of exercise on inflammation and hepatic stiffness, it has been suggested V Houttu, U Boulund et al…”

Section: Hepatic And/or Peripheral Insulin Sensitivitymentioning

confidence: 99%

The role of the gut microbiome and exercise in non-alcoholic fatty liver disease

Houttu

Boulund

Grefhorst

et al. 2020

Therap Adv Gastroenterol

View full text Add to dashboard Cite

In recent years, the human gut microbiome has been found to influence a multitude of non-communicable diseases such as cardiovascular disease and metabolic syndrome, with its components type 2 diabetes mellitus and obesity. It is recognized to be mainly influenced by environmental factors, such as lifestyle, but also genetics may play a role. The interaction of gut microbiota and obesity has been widely studied, but in regard to non-alcoholic fatty liver disease (NAFLD) as a manifestation of obesity and insulin resistance, the causal role of the gut microbiome has not been fully established. The mechanisms by which the gut microbiome influences lipid accumulation, inflammatory responses, and occurrence of fibrosis in the liver are a topic of active research. In addition, the influence of exercise on gut microbiome composition is also being investigated. In clinical trials, exercise reduced hepatic steatosis independently of weight reduction. Other studies indicate that exercise may modulate the gut microbiome. This puts forward the question whether exercise could mediate its beneficial effects on NAFLD via changes in gut microbiome. Yet, the specific mechanisms underlying this potential connection are largely unknown. Thus, associative evidence from clinical trials, as well as mechanistic studies in vivo are called for to elucidate the relationship between exercise and the gut microbiome in NAFLD. Here, we review the current literature on exercise and the gut microbiome in NAFLD.

show abstract

Randomized clinical trial: benefits of aerobic physical activity for 24 weeks in postmenopausal women with nonalcoholic fatty liver disease

Cited by 43 publications

References 38 publications

NAFLD as a Sexual Dimorphic Disease: Role of Gender and Reproductive Status in the Development and Progression of Nonalcoholic Fatty Liver Disease and Inherent Cardiovascular Risk

NAFLD as a Sexual Dimorphic Disease: Role of Gender and Reproductive Status in the Development and Progression of Nonalcoholic Fatty Liver Disease and Inherent Cardiovascular Risk

Effect of silibinin capsules combined with lifestyle modification on hepatic steatosis in patients with chronic hepatitis B

The role of the gut microbiome and exercise in non-alcoholic fatty liver disease

Contact Info

Product

Resources

About